6 related articles for article (PubMed ID: 38716593)
1. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
[TBL] [Abstract][Full Text] [Related]
2. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics.
Wu H; Wang M; Dai B; Zhang Y; Yang Y; Li Q; Duan M; Zhang X; Wang X; Li A; Zhang L
Drug Deliv; 2017 Nov; 24(1):1216-1229. PubMed ID: 28845698
[TBL] [Abstract][Full Text] [Related]
3. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
Zhou T; Chen ML; Zhang CY; Liu XY; Wang ZZ; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):225-232. PubMed ID: 38716593
[No Abstract] [Full Text] [Related]
4.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
5.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
6.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
